

CORRIGENDUM

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

W. Shi, T. Jiang, P. Nuciforo, C. Hatzis, E. Holmes, N. Harbeck, C. Sotiriou, L. Peña, S. Loi, D. D. Rosa, S. Chia, A. Wardley, T. Ueno, J. Rossari, H. Eidtmann, A. Armour, M. Piccart-Gebhart, D. L. Rimm, J. Baselga & L. Pusztai

Ann Oncol 2017; 28: 128–135 (doi: 10.1093/annonc/mdw434)

In the original article, the following funding information was omitted: ‘This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748’. This has now been added.